Heemskerk

Heemskerk Biotech is a Netherlands-based biotechnology company focused on the development of therapies for rare neurodegenerative diseases, specifically Friedreich's Ataxia (FA). The company's lead candidate, HB-001, is a small molecule therapeutic designed to restore levels of the frataxin protein, which is deficient in patients with the condition. Heemskerk Biotech leverages its expertise in molecular biology and drug screening to identify compounds that can modify disease progression rather than just managing symptoms. The company is headquartered in the Leiden Bio Science Park, a major hub for life sciences innovation in Europe. Through collaborations with patient organizations like the Friedreich's Ataxia Research Alliance, Heemskerk aims to accelerate the translation of its research into clinical treatments.